140 related articles for article (PubMed ID: 26608382)
21. Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
Wong NS; Seah EZh; Wang LZ; Yeo WL; Yap HL; Chuah B; Lim YW; Ang PC; Tai BC; Lim R; Goh BC; Lee SC
Pharmacogenet Genomics; 2011 Nov; 21(11):760-8. PubMed ID: 21849928
[TBL] [Abstract][Full Text] [Related]
22. Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.
Zhang H; Basit A; Busch D; Yabut K; Bhatt DK; Drozdzik M; Ostrowski M; Li A; Collins C; Oswald S; Prasad B
Biochem Pharmacol; 2018 Oct; 156():32-42. PubMed ID: 30086285
[TBL] [Abstract][Full Text] [Related]
23. Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene.
Ekström L; Schulze JJ; Guillemette C; Belanger A; Rane A
Pharmacogenet Genomics; 2011 Jun; 21(6):325-32. PubMed ID: 21383644
[TBL] [Abstract][Full Text] [Related]
24. Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males.
Zhu AZ; Cox LS; Ahluwalia JS; Renner CC; Hatsukami DK; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2015 May; 25(5):263-9. PubMed ID: 25794161
[TBL] [Abstract][Full Text] [Related]
25. UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study.
Wang YH; Trucksis M; McElwee JJ; Wong PH; Maciolek C; Thompson CD; Prueksaritanont T; Garrett GC; Declercq R; Vets E; Willson KJ; Smith RC; Klappenbach JA; Opiteck GJ; Tsou JA; Gibson C; Laethem T; Panorchan P; Iwamoto M; Shaw PM; Wagner JA; Harrelson JC
Clin Pharmacol Ther; 2012 Jul; 92(1):96-102. PubMed ID: 22669291
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Traina TA; Poggesi I; Robson M; Asnis A; Duncan BA; Heerdt A; Dang C; Lake D; Moasser M; Panageas K; Borgen P; Norton L; Hudis C; Dickler MN
Breast Cancer Res Treat; 2008 Sep; 111(2):377-88. PubMed ID: 17952589
[TBL] [Abstract][Full Text] [Related]
27. A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation.
Terakura S; Murata M; Nishida T; Emi N; Akatsuka Y; Riddell SR; Morishima Y; Kodera Y; Naoe T
Br J Haematol; 2005 Apr; 129(2):221-8. PubMed ID: 15813850
[TBL] [Abstract][Full Text] [Related]
28. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
29. The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk.
Angstadt AY; Berg A; Zhu J; Miller P; Hartman TJ; Lesko SM; Muscat JE; Lazarus P; Gallagher CJ
Cancer; 2013 Jul; 119(13):2477-85. PubMed ID: 23575887
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.
Eskandari-Nasab E; Hashemi M; Rezaei H; Fazaeli A; Mashhadi MA; Moghaddam SS; Arbabi F; Jahantigh M; Taheri M
Mol Biol Rep; 2012 Dec; 39(12):10531-9. PubMed ID: 23053953
[TBL] [Abstract][Full Text] [Related]
31. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
[TBL] [Abstract][Full Text] [Related]
32. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.
Swanson C; Mellström D; Lorentzon M; Vandenput L; Jakobsson J; Rane A; Karlsson M; Ljunggren O; Smith U; Eriksson AL; Bélanger A; Labrie F; Ohlsson C
J Clin Endocrinol Metab; 2007 Dec; 92(12):4878-82. PubMed ID: 17698910
[TBL] [Abstract][Full Text] [Related]
33. Impact of the UGT2B17 polymorphism on the steroid profile. Results of a crossover clinical trial in athletes submitted to testosterone administration.
Martín-Escudero P; Muñoz-Guerra JA; García-Tenorio SV; Garde ES; Soldevilla-Navarro AB; Galindo-Canales M; Prado N; Fuentes-Ferrer ME; Fernández-Pérez C
Steroids; 2019 Jan; 141():104-113. PubMed ID: 30503386
[TBL] [Abstract][Full Text] [Related]
34. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen.
Ariazi EA; Leitão A; Oprea TI; Chen B; Louis T; Bertucci AM; Sharma CG; Gill SD; Kim HR; Shupp HA; Pyle JR; Madrack A; Donato AL; Cheng D; Paige JR; Jordan VC
Mol Cancer Ther; 2007 Nov; 6(11):2817-27. PubMed ID: 17989318
[TBL] [Abstract][Full Text] [Related]
35. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
Watanabe T; Sano M; Toi M; Saeki T; Kanda K; Miura S; Inaji H; Sono H; Saeki H; Nishimura R; Fujita Y
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1211-21. PubMed ID: 12146002
[TBL] [Abstract][Full Text] [Related]
36. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.
Valle M; Di Salle E; Jannuzzo MG; Poggesi I; Rocchetti M; Spinelli R; Verotta D
Br J Clin Pharmacol; 2005 Mar; 59(3):355-64. PubMed ID: 15752382
[TBL] [Abstract][Full Text] [Related]
37. Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism.
Strahm E; Mullen JE; Gårevik N; Ericsson M; Schulze JJ; Rane A; Ekström L
Drug Test Anal; 2015; 7(11-12):1063-70. PubMed ID: 26198073
[TBL] [Abstract][Full Text] [Related]
38. Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years.
Zhang H; Basit A; Wolford C; Chen KF; Gaedigk A; Lin YS; Leeder JS; Prasad B
Clin Pharmacol Ther; 2020 May; 107(5):1149-1158. PubMed ID: 31900930
[TBL] [Abstract][Full Text] [Related]
39. Intestinal Metabolism of Diclofenac by Polymorphic UGT2B17 Correlates with its Highly Variable Pharmacokinetics and Safety across Populations.
Ahire D; Heyward S; Prasad B
Clin Pharmacol Ther; 2023 Jul; 114(1):161-172. PubMed ID: 37042794
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis reveals a lack of association between UGT2B17 deletion polymorphism and tumor susceptibility.
Deng X; Cheng Y; Yang X; Li S; Zhao R; Liu K; Liu J; Cao Q; Qin C; Shao P; Meng X; Li J; Lu Q; Yin C
PLoS One; 2014; 9(5):e96812. PubMed ID: 24802609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
